Johnson & Johnson, Alexandria Venture Investments and Serum Institute of India contributed to a series A for Albert Einstein College of Medicine spinout X-Vax.

X-Vax Technology, a US-based herpes vaccine developer based on research at Albert Einstein College of Medicine, received $56m on Tuesday in a series A round featuring Johnson & Johnson Innovation – JJDC, the corporate venturing vehicle for medical products group Johnson & Johnson.
The round included Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities, in addition to immunobiological drug developer Serum Institute of India, impact investment fund Adjuvant Capital…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?